HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • Will Improving Adherence Optimize Medication Use?
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
You are here: Home / Archives for Biosimilars

Biosimilar Uptake in E.U. Affected by National Policies

Although the European Union has marked solid strides in the way of biosimilars, the overall uptake in individual nations is heavily impacted by domestic policy. A new paper published in PLOS One details some of the initiatives and regulations affecting biosimilars in the E.U. The paper also […]

more info 01/07/2018View Related Articles
Bookmark and Share

WHO Commits to Biosimilar Medicine Prequalification Program

The World Health Organization (WHO) is planning on launching a new pilot program, a Biosimilar Medicine Prequalification Program, to assess cheap copies of expensive biotech cancer drugs, making these medicines more widely available. Find out more here. (Source: dispatch tribunal, 5/8/17) […]

more info 05/25/2017View Related Articles
Bookmark and Share

The Biosimilars Forum Releases Statement on EMA Information Guide

The Biosimilars Forum recently issued a statement addressing the newly released EMA information guide on biosimilars for healthcare professionals. Hear what they had to say here. (Source: Biosimilars Forum, 5/16/17) […]

more info 05/19/2017View Related Articles
Bookmark and Share

US Supreme Court to Weigh in on Biosimilar ‘Patent Dance’

In somewhat of a surprise decision, The US Supreme Court recently decided to to review whether biosimilar companies should have to wait six months after US Food and Drug Administration (FDA) approval before launching their follow-on products. Find out more here. (Source: Zachary Brennan, RAPS, […]

more info 04/13/2017View Related Articles
Bookmark and Share

Are Biosimilars the ‘Magic Bullet’ to Drug Prices?

Has American uptake of Biosimilars been too slow? How do payers perceive what's important, and what can companies do to ensure commercial success? Stay ahead in the biosimilars space and download this first word report, Biosimilars: US Payer Perspectives today! […]

more info 04/10/2017View Related Articles
Bookmark and Share

Knowledge Gaps Persist for Biosimilars

A recent presentation at the AMCP Annual Meeting gave an update on the latest in biosimilars and discussed the continued knowledge gaps in the health industry surrounding the use of biosimilars. Find out more here. (Source: AMCP) […]

more info 04/04/2017View Related Articles
Bookmark and Share

Check Out This Week’s HealthEconomics.Com’s Newsletter

HealthEconomics.Com's weekly newsletter is out! Never worry about missing something big in the news, we take the Top Stories of the week, the most important happenings, and upcoming events and put them together in our weekly newsletter - keeping you up-to-date and in the know! If you would like to […]

more info 04/04/2017View Related Articles
Bookmark and Share

The Biosimilar Pipeline is Bursting with Possibilities

Biosimilarpipeline recently reported more than 700 biosimilars currently in development with more than 660 companies involved in the biosimilar land rush. The number of biosimilars in development however, far exceeds the number of agents that will be approved in the near future. Find out more here. […]

more info 03/29/2017View Related Articles
Bookmark and Share

Can Pharma get Physicians on Board with Biosimilars?

Payers are enthusiastic about the savings biosimilars bring but warn that physician fear, stoked by a lack of data, clinical inexperience and misinformation, is limiting biosimilar uptake. Take a look at payers candid views of biosimilars in FirstWord's Biosimilars: European Payer Perspectives […]

more info 02/07/2017View Related Articles
Bookmark and Share

How Will Pricing Wars Shape the RA Landscape?

In Europe, and soon to be in the US, anti-TNF biosimilars represent the best chance for much needed cost savings in the rheumatoid arthritis (RA) market. Find out how the looming price war will shape the RA landscape in FirstWord's Payer Insight: Rheumatoid Arthritis. (Source: FirstWord, 2017) […]

more info 01/25/2017View Related Articles
Bookmark and Share

Take a Virtual Look Inside Biotech Manufacturing

Ever wonder what the inside of a biologic medicines manufacturing facility looks like? Take this virtual tour for a rare look at the highly unique manufacturing facility at Amgen. Step by step, the video takes you through the whole process of product development, all the way to packaging and […]

more info 12/20/2016View Related Articles
Bookmark and Share

Check Out This New Specialty Pharma Website

Janssen Biotech, Inc., and Avalere Health recently announced the launch of the new DIMENSIONS website. The site will provide specialty pharmaceutical market stakeholders access to future trends and insights through DIMENSIONS issue briefs, webinars, and data on various topics including:Alternative […]

more info 09/15/2016View Related Articles
Bookmark and Share

Payer/Provider Collaboration to Promote Biosimilar Optimization

A panel was convened to share ideas, discuss challenges, and develop practical solutions to promote optimal utilization in order to encourage collaboration between payers and providers to help ensure the success of biosimilar entrants into the marketplace. Learn more here. (Source: Chronis Manolis, […]

more info 09/15/2016View Related Articles
Bookmark and Share

Biosimilars – Will the U.S. Ever Catch Up to Europe?

The U.S. Biosimilar market lags almost a decade behind that in Europe. Find 7 key questions asked and answered about the progress made, and what still lies ahead, here. (Source: Dave Picard, Knowledge driven, 8/4/16) […]

more info 09/06/2016View Related Articles
Bookmark and Share

2016 – The Future of Biosimilars

A new FirstWord report, The Future of Biosimilars 2016, includes first-hand insight from patient groups, physicians, lawyers, and stakeholders from originator and biosimilar companies. Learn about developers’ market access strategies, originators’ efforts to keep them at bay, key drivers for […]

more info 08/05/2016View Related Articles
Bookmark and Share

How Similar are Biosimilars to Branded Counterparts?

This new study finds biosimilar TNF-a inhibitors appear to be comparable to their branded counterparts. Find out more here. (Source: dsn Drug Store News, 2016) […]

more info 08/04/2016View Related Articles
Bookmark and Share

Is the U.S. Ready for the Biosimilar Boom?

Biosimilars haven't really taken off in the United States yet, but every industry player wants in. Leading companies, such as Merck are already taking steps to help promote biosimilar acceptance, Find out more here. (Source: Larry Dobrow, MM&M, 5/25/16) […]

more info 06/09/2016View Related Articles
Bookmark and Share

Event Highlights From AMCP 2016 Annual Meeting

Cost was a key focus at AMCP 2016, with all members of industry raising a range of questions and concerns for how cost affects pharmaceuticals. See here for a more in depth look at some of the specific discussions and studies that took up the issue of cost within the industry. Following are […]

more info 04/22/2016View Related Articles
Bookmark and Share

Specialty Pharmacy Highlights at AMCP Annual Meeting

AMCP recently began their most ambitious specialty pharmacy pre-meeting program, the inaugural Specialty Pharmacy Connect. Learn more here. (Source: Susan Cantrell, Managed Healthcare Executive, 4/18/16) […]

more info 04/22/2016View Related Articles
Bookmark and Share

Biosimilars – Ready, Set, Launch

In March of 2015, the AMCP convened a biosimilar Partnership Forum to address current readiness of MCOs, Identify gaps, challenges, and opportunities, and to recommend education and training content. Learn more here. (Source: JMCP, Volume 22 Issue (4), April 2016) […]

more info 04/12/2016View Related Articles
Bookmark and Share

Market Access Week in Review

Last week was a good week, full of impactful news on biosimilars and insurer consolidation. Read more here. (Source: DRG- Training, 4/5/16) […]

more info 04/07/2016View Related Articles
Bookmark and Share

FDA Releases Draft Guidance on Biosimilar Labeling

The United States Food and Drug Administration (FDA) recently unveiled a 15 page draft guidance on biosimilar labels. Learn more. (Source: Zachary Brennan, RAPS, 3/31/16) […]

more info 04/04/2016View Related Articles
Bookmark and Share

How Will Value-Based Pricing Affect Biosimilar Uptake?

Given Big Pharma's increasing attention to value-based deals, this author questions where biosimilars will fit in to it all. Learn more here. (Source: Anna Rose Welch, Bioprocess Online, 3/3/16) […]

more info 03/10/2016View Related Articles
Bookmark and Share

15 AMCP Nexus 2016 Sessions Added to AMCP Learn

Are you looking for cutting-edge information on the hottest managed care pharmacy topics of the day, and an opportunity to earn continuing pharmacy education credits? AMCP recently repurposed 15 of its most popular live sessions from AMCP Nexus 2015 as online AMCP Learn programs, available here. […]

more info 02/11/2016View Related Articles
Bookmark and Share

What is Driving the Uptake of Biosimilars in Europe?

This First Word report, Biosimilars: European Payer Perspectives (2016), identifies the issues that payers identify as critical to the continued growth and adoption of biosimilars. Available for purchase here. (Source: FirstWord, January 2016) […]

more info 01/20/2016View Related Articles
Bookmark and Share

2015 Year in Review for New Medicine Approvals

Last year was an exceptional year for FDA drug approvals with a record 45 new medicines. Read more here. (Source: Holly Campbell, PhRMA, 1/11/16) […]

more info 01/13/2016View Related Articles
Bookmark and Share

What Will the FDA Decide on Biosimilars? Payers are Waiting

The Biosimilar market has plenty of hurdles to clear before reaching it's full potential in United States healthcare, and right now, it all seems to be hinging on final guidance from the Food and Drug Administration (FDA). Read more here. (Source: 1/1/16Managed Healthcare Executive, Aine Cryts) […]

more info 01/06/2016View Related Articles
Bookmark and Share

What Will Formulary Committees do with Biosimilars?

Formulary committees will have a number of new considerations to keep in mind with the introduction of biosimilar drugs. See 4 factors that should be considered here. (Source: First Report Managed Care, 11/13/15) […]

more info 11/16/2015
Bookmark and Share

Biologics & Biosimilars Collective Intelligence Consortium

Managed care organizations have devoted significant resources to develop an infrastructure that makes possible active surveillance of biosimilars in distributed research networks (DRNs). AMCP plans to marshal these resources for the important public health benefit inherit in monitoring biosimilar […]

more info 11/10/2015View Related Articles
Bookmark and Share

Biosimilars: Regulatory Outlook

This 64 page report gives in-depth and candid views on what eight industry and biosimilar experts see as the areas that require the most attention within biosimilar regulation. Available for purchase here. (Source: FirstWord, November 2015) […]

more info 11/04/2015View Related Articles
Bookmark and Share

  • 1
  • 2
  • 3
  • Next Page

 

View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Conference of the Week:

Link of the Week:

Job of the Week:

Webinar of the Week:

White Papers

  • The Future Was Today
  • How Can a Supply Chain Dashboard Yield Greater Clinical Trial Insights, Cost Control, and Efficiency?
  • Strategies for Engaging Vulnerable Populations in Healthcare
  • Tracing the health care experience informs decision-making
  • Driving More Value and Cost Savings With SDOH Data
  • Advancing Early Stage Oncology Research with Adaptive Designs and Master Protocols
  • Transformation of Clinical Trial Design and Operations
  • Using real-world data to close the rare disease data gap
  • Analysis and Insights from Real-World Clinical Registries: RA, GCA, JIA, & SLE
  • The role of real-world evidence in FDA approvals
  • Cytel Scientists Call for a “Statistician-First Workflow” to Optimize Drug Development
  • Specialty Pharmacy Virtual Technology Adoption on the Rise
  • Clinical Trials Have Changed. Has Your Tech Strategy?
  • Beyond COVID-19: Life sciences reimagined
  • How Real-World Evidence Can Support Adoption of New Technology
  • Interventional Studies
  • Virtual Expanded Access Program Providing Breast Cancer Patients Early Access to Treatment During the COVID-19 Pandemic
  • Pediatric Drug Development: Trends and Perspectives in the United States
  • Can Clinical Studies Go Virtual?
  • ICER’s impact on payer decision making
  • Representation and Diversity in Clinical Trials
  • Advisory Boards: The Good, The Bad, and The Ugly
  • An Initial Framework to Describe and Classify Integrated Scientific Advice Procedures
  • Ensuring timely dissemination of research: a guide to working as a medical publications professional
  • Patient Intelligence and Insights Reports
  • Adaptive Trial Designs in Early Oncology: Minimizing Risk & Accelerating Timelines
  • Patient Centricity
       Exploring the patient dynamic from different perspectives
  • How to Excel at Next Generation Trial Execution
  • Payers: The New Catalysts of Better Health
  • A writer’s role in drug development: a guide to getting started in regulatory medical writing

Syndicated Reports

  • Bioinformatics Market Research Report by Product, by End User – Global Forecast to 2025 – Cumulative Impact of COVID-19
  • Health Economics & Outcomes Research (HEOR) Services Market to 2027
  • Healthcare Artificial Intelligence Market by Product and Services – Global Forecast to 2027
  • Bioinformatics Market – Growth, Share, Opportunities & Competitive Analysis, 2020 – 2028
  • Big Data and AI in Market Access
  • Altruista Health Payer Index Survey 2020 Report
  • Innovations in Drug Pricing and Reimbursement 2020
  • Healthcare Reimbursement Market Value forecast, New Business Opportunities and Companies: Outlook by Type, Application, by End User and by Country, 2020-2026
  • Real World Data for Orphan Drugs: Meeting the Data Analysis Challenge
  • Directory of Health Plans: Trusted Health Insurance Plan Enrollment and Affiliation Data
  • Global Value-Based Reimbursement Software Market Report
  • Health Economics & Outcomes Research (HEOR) Services Market: Emerging industries, Challenges and Threats Faced by Key Vendors(Axtria, Avalon Health Economics, Cardinal Health, ICON, IQVIA, McKesson, MEDLIOR, Optum, PharmaLex, (PPD), RTI)
  • World Preview 2019, Outlook to 2024
  • Provider Perceptions of Value-Based Care
  • Healthcare Industry’s Response to COVID-19
  • Value-Based Care Assessment
  • Pharmacy Benefit Management Market in US – Industry Outlook and Forecast 2020-2025
  • 2025 Growth: Healthcare Reimbursement Market set to grow with massive rate by 2020 to 2025
  • Global Specialty Pharmaceutical Market 2020- Pfizer, Roche, Amgen, AbbVie
  • 3 Trends to Accelerate Time to Market
  • Scientific Research And Development Services Global Market Report 2020-30: Covid 19 Impact and Recovery
  • Engaging with ICER: Lessons and insights for pharma
  • COVID-19 Implications for pharma: US payer insights
  • Pricing and Reimbursement in Oncology
  • Digital Technologies: New Strategies for Customer Engagement
  • Real World Evidence (RWE) Solutions Market by Component, Application, End User – Global Forecast to 2024
  • 2019 Healthcare Benchmarks: Social Determinants of Health
  • Pricing Transparency in Pharma
  • Medical Affairs: The Roadmap to 2025
  • Health Economics & Outcomes Research (HEOR) Services Market Share & Forecast, 2020–2026
HealthEconomics.Com

HealthEconomics.Com

  • Become a Better Writer!
  • HealthEconomics.Com Recognized as Top Influencer at ISPOR International Meeting in Washington DC
  • Will ICER Framework Destroy Progress Against Multiple Myeloma?
  • Celgene Unleashes the Power of Data into Clinical Trial Design
  • How Well is Harvoni Working in the Real World?
  • New CVS and Express Scripts Value Based Plans for Oncology
  • Oversized Cancer Drug Vials Waste $3B Each Year
  • Can More Data Make Providers’ Jobs Easier?
  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Take This Survey for a Chance to Win $200!
  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • ICER Releases Two Draft Reports on Obeticholic Acid
  • What do Patient Advocates Think of New ICER Report?
  • Could a New ICER Report Put Patients at Risk?
  • Contact Us

About

  • International Myeloma Foundation Responds to ICER Report
  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HE Institute

Strategy, Training, Education, and Communications in HEOR & Market Access.

Innovation Webinar

Big ideas accelerating change in HEOR, RWE and Health Technology. Learn more!

tHEORetically Speaking Blog

Insights and observations for HEOR, market access, pricing, reimbursement, and health policy.

HE Jobs Portal

Your Premier Employment Source for HEOR, Market Access, and Real World Evidence

HE Webinars

Online educational and informational seminars for HEOR, market access, pricing, and reimbursement.
  • Doctor Evidence Launches GROWTH Replicator Program
  • Is PCORI Underfunding CER?
  • HealthEconomics.Com
  • About HealthEconomics.Com
  • Advertising Inquiries
  • Careers
  • Contact HealthEconomics.Com

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • Will Improving Adherence Optimize Medication Use?
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute